Artivion | CRY - Gross Profit On Sales

Stock Price
37.76
Daily Change
0.60 1.61%
Monthly
4.54%
Yearly
58.39%
Q2 Forecast
36.95

Artivion reported $73.14M in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
Abbott USD 5.86B 675M Mar/2026
Accuray USD 41.89M 7.42M Dec/2024
AngioDynamics USD 44.78M 2.93M Sep/2025
Artivion USD 73.14M 1.25M Dec/2025
AtriCure USD 105.34M 4M Dec/2025
Baxter International USD 577M 373M Dec/2025
Becton, Dickinson and Co. USD 2.41B 1.72B Dec/2025
Boston Scientific USD 3.61B 64M Mar/2026
Edwards Lifesciences USD 1.29B 59.4M Mar/2026
Inogen USD 41.34M 1.39M Sep/2024
Integra LifeSciences USD 217.1M 10.11M Dec/2025
J&J USD 17.24B 642M Mar/2026
Mesa Laboratories USD 39.75M 4.3M Dec/2024
Orthofix International USD 153.28M 4.76M Dec/2025
Pfizer USD 3.54B 7.61B Sep/2025
ResMed USD 878.72M 57.9M Dec/2025
Stryker USD 4.49B 633M Dec/2025
Surmodics USD 20.08M 31.62M Jun/2025
Tandem Diabetes Care USD 167.46M 33.17M Dec/2025
Teleflex USD 307.45M 144.2M Dec/2025
Terumo JPY 153.19B 6.2B Dec/2025
Trinity Biotech USD 6.47M 1.59M Sep/2025